Liquid biopsy group Angle said the University of Basel in Switzerland had published breakthrough research using the company's technology, into the role of reduced oxygen levels in promoting breast cancer metastasis. The research suggested that intra-tumour hypoxia creates conditions that stimulate the formation of an increased number and size of circulating tumour cells clusters, which may increase the metastatic spread of the cancer. Angle said the study demonstrated key capabilities of its Parsortix system to support cancer drug discovery. It also exemplified the utility of the Parsortix system in isolating metastatic breast cancer circulating tumour cells clusters, it added. At 2:12pm: (LON:AGL) Angle PLC share price was +0.1p at 53.6p
0.00 (0.00%)delayed 16:57PM
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.